Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

NCT07293325 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medications semaglutide or tirzepatide can slow biological aging in adults with obesity by measuring changes in DNA methylation.

Status Recruiting Currently enrolling participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 66 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2025-06 · est. completion 2027-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07293325 ↗

Description as written by the study sponsor.

This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months. Participants will receive semaglutide, tirzepatide, or metformin for 24 weeks. Changes in "biological (epigenetic) age" will be assessed using the iWatchAge DNA methylation age test, while simultaneously monitoring improvements in aging-related biomarkers such as inflammatory factors, metabolic parameters, and body composition. The aim is to determine whether incretin-based therapies can reverse or slow obesity-related accelerated epigenetic aging and to provide new clinical evidence for interventions targeting obesity and aging.

Treatments tested

Semaglutide Drug

Semaglutide administered once weekly by subcutaneous injection.Dose titrated from 0.25 mg to 2.0 mg as tolerated over 24 weeks
Tirzepatide Drug

Tirzepatide administered once weekly by subcutaneous injection. Dose titrated from 2.5 mg to 10 mg as tolerated over 24 weeks
Metformin Drug

Metformin administered orally. Dose titrated from 500 mg to 1500-2000 mg daily, based on tolerance, for 24 weeks

Main thing measured	Change in DNA methylation-based biological age measured by iWatchAge
Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions studied	Adults With Simple Obesity
GLP-1 drugs	semaglutide, tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07293325 ↗